Plus Therapeutics will participate in the H.C. Wainwright Global Investment Conference with a fireside chat on CNS cancer therapies.
Quiver AI Summary
Plus Therapeutics, Inc. will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, where CEO Dr. Marc H. Hedrick will engage in a fireside chat with H.C. Wainwright's Sean Lee. The discussion will be available on demand for registered investors starting September 5. Plus Therapeutics is a Houston-based clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, particularly leptomeningeal metastases and recurrent glioblastoma. The company is advancing its product pipeline through innovative technologies, strategic partnerships, and aims to enhance treatment outcomes for challenging cancers. For more information, visit their website.
Potential Positives
- Participation in the H.C. Wainwright 27th Annual Global Investment Conference enhances the company's visibility and provides an opportunity to attract potential investors.
- Dr. Marc H. Hedrick's involvement in a fireside chat with a VP of Equity Research demonstrates leadership engagement with the investment community, potentially strengthening investor confidence.
- The company's focus on developing targeted radiotherapeutics for CNS cancers addresses a significant medical need, highlighting its commitment to improving clinical outcomes for difficult-to-treat conditions.
Potential Negatives
- None
FAQ
What is Plus Therapeutics participating in on September 8 – 10, 2025?
Plus Therapeutics will participate in the H.C. Wainwright 27th Annual Global Investment Conference.
Who will represent Plus Therapeutics at the conference?
Marc H. Hedrick, M.D., Plus Therapeutics President and CEO, will represent the company at the conference.
When will the fireside chat be available on demand?
The fireside chat will be available on demand beginning Friday, September 5 at 7:00am ET.
How can investors request a meeting with Dr. Hedrick?
Investors can request a one-on-one meeting with Dr. Hedrick through the conference registration link provided in the announcement.
What type of therapies does Plus Therapeutics focus on?
Plus Therapeutics develops targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PSTV Insider Trading Activity
$PSTV insiders have traded $PSTV stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PSTV stock by insiders over the last 6 months:
- ROBERT P LENK purchased 110,000 shares for an estimated $53,779
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PSTV Hedge Fund Activity
We have seen 11 institutional investors add shares of $PSTV stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AIGH CAPITAL MANAGEMENT LLC removed 560,905 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $532,915
- JANE STREET GROUP, LLC added 117,454 shares (+inf%) to their portfolio in Q2 2025, for an estimated $40,850
- HRT FINANCIAL LP removed 102,065 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $35,498
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 80,505 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $27,999
- UBS GROUP AG added 54,201 shares (+162.1%) to their portfolio in Q2 2025, for an estimated $18,851
- VIRTU FINANCIAL LLC removed 40,030 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $13,922
- GOLDMAN SACHS GROUP INC added 26,753 shares (+inf%) to their portfolio in Q2 2025, for an estimated $9,304
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PSTV Analyst Ratings
Wall Street analysts have issued reports on $PSTV in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Maxim Group issued a "Buy" rating on 08/18/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/27/2025
- Ascendiant Capital issued a "Buy" rating on 06/05/2025
To track analyst ratings and price targets for $PSTV, check out Quiver Quantitative's $PSTV forecast page.
$PSTV Price Targets
Multiple analysts have issued price targets for $PSTV recently. We have seen 4 analysts offer price targets for $PSTV in the last 6 months, with a median target of $6.0.
Here are some recent targets:
- Jason McCarthy from Maxim Group set a target price of $3.0 on 08/18/2025
- Sean Lee from HC Wainwright & Co. set a target price of $3.0 on 06/27/2025
- Jason Kolbert from D. Boral Capital set a target price of $9.0 on 06/25/2025
- Edward Woo from Ascendiant Capital set a target price of $20.5 on 06/05/2025
Full Release
HOUSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it will participate in the H.C. Wainwright 27 th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel.
Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer will participate in a fireside chat with Sean Lee, VP of Equity Research at H.C. Wainwright. The fireside chat will be available on demand beginning Friday, September 5 at 7:00am ET for registered investors of the conference. To request a one-on-one meeting with Dr. Hedrick and to register for the conference, click below:
https://hcwevents.com/annualconference/
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit
https://plustherapeutics.com/
.
Investor Contact
CORE IR
[email protected]
